Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) generates frequent news as a clinical-stage biopharmaceutical company advancing late-stage small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Company announcements emphasize progress in its two core programs, MN-166 (ibudilast) and MN-001 (tipelukast), across multiple serious conditions.
News updates commonly cover clinical trial milestones, such as completion of patient enrollment, trial design details, and presentations at major scientific meetings. Examples include the COMBAT-ALS Phase 2b/3 trial of MN-166 in amyotrophic lateral sclerosis, the OXTOX study in chemotherapy-induced peripheral neuropathy, and the MN‑001‑NATG‑202 Phase 2 trial in hypertriglyceridemia and non-alcoholic fatty liver disease due to type 2 diabetes.
Investors and observers can also expect scientific and mechanistic updates, including peer-reviewed publications on MN-001 and its metabolite MN-002 in cholesterol and lipid metabolism, as well as letters from the CEO explaining how new data support the company’s development strategy. Regulatory and advisory appointments, such as the addition of experienced clinical and regulatory advisors, are another regular theme in MediciNova’s news flow.
Because MediciNova is listed on Nasdaq and the Tokyo Stock Exchange, its news often includes capital markets and investor relations events, such as conference presentations and corporate overviews for institutional and individual investors. This news page aggregates these developments so readers can follow clinical progress, scientific publications, regulatory interactions, and corporate updates related to MNOV in one place.
MediciNova, Inc. has announced a partnership with BARDA to repurpose its drug MN-166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung damage. This collaboration falls under BARDA's ReDIRECT program, which provides funding for proof-of-concept studies in preclinical models. MN-166 has shown efficacy in reducing pulmonary injury in animal models and has been administered to over 800 clinical trial participants. The drug is also in late-stage development for several neurological disorders and COVID-19-related ARDS.
MediciNova, a biopharmaceutical company trading as MNOV, announced its participation in the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. CEO Yuichi Iwaki and VP Geoffrey O'Brien will hold one-on-one investor meetings, facilitated by Maxim Group. MediciNova focuses on developing small-molecule therapeutics for diseases such as progressive multiple sclerosis and substance dependence, with key products including MN-166 and MN-001. The conference will feature discussions and presentations from various issuers, enhancing visibility for emerging growth companies.
MediciNova, Inc. has announced the discontinuation of its SARS-CoV-2 vaccine development due to the presence of established vaccines and those in advanced development. This strategic decision aims to redirect resources toward other critical programs with significant unmet medical needs and market potential. MediciNova's focus will now remain on therapies like MN-166 for neurological disorders and MN-001 for treating fibrotic diseases, ensuring its alignment with larger medical opportunities.
MediciNova, a biopharmaceutical company trading under NASDAQ:MNOV, has completed a private placement of $20 million in stock to 3D Opportunity Master Fund. The funding will support three key initiatives: starting a pivotal clinical trial for MN-166 (ibudilast) in glioblastoma, developing an intravenous formulation of MN-166 for ALS patients, and initiating a Phase 2 trial for MN-001 (tipelukast) in NASH. The company aims to address unmet medical needs in various neurological and fibrotic diseases.
MediciNova has announced positive results from a study on MN-001 (tipelukast) in an acute liver injury model. The findings will be presented at The Liver Meeting Digital Experience™ 2020 by researchers from the University of Louisville. MN-001, an orally bioavailable compound, exhibits anti-inflammatory and anti-fibrotic activities, potentially making it viable for treating fibrotic diseases like NASH and IPF. The poster presentation is scheduled for November 13-16, 2020, showcasing the study’s contributions to fibrosis research.
MediciNova, Inc. reported positive clinical findings for MN-166 (ibudilast) in preventing chemotherapy-induced peripheral neuropathy (CIPN), as detailed in Cancer Chemotherapy and Pharmacology. A pilot study involving 14 patients revealed that co-treatment with MN-166 improved or stabilized neurotoxic symptoms caused by oxaliplatin. Notably, 10 out of 12 participants showed no worsening of symptoms. Pharmacokinetic analysis indicated MN-166 did not affect oxaliplatin exposure. The results suggest MN-166 may play a significant role in enhancing the quality of life for cancer patients undergoing chemotherapy.
MediciNova, Inc. announced promising results for its intranasal SARS-CoV-2 vaccine prototype using BC-PIV technology, which successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies in mice. The study confirmed high antibody titers against the S1 antigen, indicating potential efficacy in generating immune responses. CEO Yuichi Iwaki expressed optimism about the results and future developments. The BC-PIV platform is designed to administer vaccines intranasally, which could enhance local immunity against COVID-19.
MediciNova, a biopharmaceutical company traded on NASDAQ (MNOV), announced that its partner BioComo's vaccine for the Respiratory Syncytial (RS) virus has successfully induced strong neutralizing antibodies in mice. This development supports MediciNova's ongoing work on an intranasal SARS-CoV-2 vaccine, leveraging the same BC-PIV technology. The study was conducted at Fraunhofer Institute for Cell Therapy and Immunology in Germany. CEO Yuichi Iwaki expressed optimism about the vaccine's efficacy and looks forward to future progress updates.
MediciNova presented positive results from its Phase 2 trial of MN-166 (ibudilast) for Alcohol Use Disorder (AUD) at the American Psychological Association 2020 Annual Convention. The study, involving 52 patients, showed that ibudilast significantly reduced heavy drinking days (p=0.03) and attenuated brain activation in response to alcohol cues (p=0.02). CEO Yuichi Iwaki noted the product’s potential to address AUD, an area of high unmet medical need. The study was funded by a National Institute on Drug Abuse grant.
MediciNova has entered a collaboration with BioComo and Mie University to co-develop a SARS-CoV-2 vaccine utilizing the BC-PIV vector technology. This innovative approach employs a recombinant human parainfluenza virus type 2, which showcases high immunogenicity and safety in producing vaccines. The partnership is positioned to leverage previous successes in vaccine development, including for Ebola and Respiratory Syncytial virus. The vaccine aims to be available in both intra-nasal and intra-muscular formats to enhance local immunity against COVID-19.
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
